MEI Pharma Inc  

(Public, NASDAQ:MEIP)   Watch this stock  
Find more results for MEIP
-0.01 (-0.64%)
Apr 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.55 - 1.62
52 week 1.23 - 2.28
Open 1.57
Vol / Avg. 0.00/136,372.00
Mkt cap 56.63M
P/E     -
Div/yield     -
EPS -0.12
Shares 36.77M
Beta 1.27
Inst. own 18%
Apr 4, 2017
MEI Pharma, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-04-2017 04:20 PM - Webcast
Mar 21, 2017
MEI Pharma Inc at Oppenheimer Healthcare Conference
Feb 8, 2017
Q2 2017 MEI Pharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 69.10% -
Operating margin 68.70% -
EBITD margin - -
Return on average assets 79.95% -37.28%
Return on average equity 98.07% -41.13%
Employees 23 -
CDP Score - -


11975 El Camino Real Ste 101
SAN DIEGO, CA 92130-2541
United States - Map
+1-858-7926300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Officers and directors

Christine Anna White M.D. Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Daniel P. Gold Ph.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Thomas M. Zech Chief Financial Officer, Secretary
Age: 65
Bio & Compensation  - Reuters
David M. Urso Senior Vice President of Corporate Development, General Counsel
Age: 52
Bio & Compensation  - Reuters
Robert D. Mass M.D. Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Charles V. Baltic III Independent Director
Age: 55
Bio & Compensation  - Reuters
Kevan E. Clemens Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Nicholas R. Glover Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Thomas C. Reynolds M.D. Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
William Dodge Rueckert Independent Director
Age: 63
Bio & Compensation  - Reuters